Moleculin Biotech Inc (MBRX NASDAQ) stock market data APIs
$4.8473
0.8(16.5%)
as of December 10, 2025
Try our APIs with
free plan!
Moleculin Biotech Inc Financial Data Overview
Price chart is built with
Anychart
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose for the treatment of pathogenic viruses and various cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Prev. Close
4.8473
Open
5.6488
High
5.9103
Low
4.7899
52 wk Range
4.75-69.5
Market Cap
22 467 K
Shares Outstanding
49 499 K
EPS
-0.68
Beta
1.551
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Moleculin Biotech Inc data using free add-ons & libraries
Get Moleculin Biotech Inc Fundamental Data
Moleculin Biotech Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -25 320 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-17
- EPS/Forecast: -0.2633
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Moleculin Biotech Inc News
New
Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026
Continues to drive enrollment with increase to 78% now consented Blinded response activity tracking within expected range Consented subjects now across seven countries supporting the expansion of ...
Moleculin Announces New Annamycin Collaboration in Brain Tumors
Investigator-Initiated Preclinical studies at CIC biomaGUNE aimed at combatting Glioblastoma Multiforme Research will evaluate effects of intra-arterial delivery of Annamycin HOUSTON, Dec. 08, 2025...
Moleculin Biotech To Present Corporate Overview At Virtual Investor Closing Bell Series
(RTTNews) - Moleculin Biotech Inc. (MBRX) announced that it will participate in the Virtual Investor Closing Bell Series on Tuesday, December 2, 2025, at 4:00 PM ET. Chairman and Chief Executive Offic...
Moleculin to Participate in the Virtual Investor Closing Bell Series
Live video webcast with Walter Klemp, Chairman and Chief Executive Officer, on Tuesday, December 2nd at 4:00 PM ET HOUSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX)...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
